KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Cash from Investing Activities (2016 - 2025)

Neogenomics (NEO) has disclosed Cash from Investing Activities for 16 consecutive years, with -$6.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 15.33% year-over-year to -$6.3 million, compared with a TTM value of -$12.3 million through Dec 2025, down 195.96%, and an annual FY2025 reading of -$12.3 million, down 195.96% over the prior year.
  • Cash from Investing Activities was -$6.3 million for Q4 2025 at Neogenomics, down from -$277000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $23.7 million in Q1 2023 and bottomed at -$453.4 million in Q2 2021.
  • Average Cash from Investing Activities over 5 years is -$27.7 million, with a median of -$2.3 million recorded in 2022.
  • The sharpest move saw Cash from Investing Activities plummeted 2396.34% in 2021, then soared 1717.59% in 2023.
  • Year by year, Cash from Investing Activities stood at -$9.6 million in 2021, then skyrocketed by 88.91% to -$1.1 million in 2022, then skyrocketed by 1717.59% to $17.2 million in 2023, then plummeted by 131.79% to -$5.5 million in 2024, then dropped by 15.33% to -$6.3 million in 2025.
  • Business Quant data shows Cash from Investing Activities for NEO at -$6.3 million in Q4 2025, -$277000.0 in Q3 2025, and -$9.3 million in Q2 2025.